Barclays Starts IDEXX Laboratories (IDXX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IDXX Hot Sheet
Price: $672.04 --0%
Rating Summary:
13 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
13 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Barclays analyst Glen Santangelo initiates coverage on IDEXX Laboratories (NASDAQ: IDXX) with a Overweight rating and a price target of $850.00.
For an analyst ratings summary and ratings history on IDEXX Laboratories click here. For more ratings news on IDEXX Laboratories click here.
Shares of IDEXX Laboratories closed at $714.10 yesterday.
You May Also Be Interested In
- IDEXX Laboratories (IDXX) PT Raised to $770 at Jefferies
- Guggenheim Starts Lockheed Martin (LMT) at Buy
- Bernstein SocGen Group Starts GlaxoSmithKline Pharmaceuticals (GLXO:IN) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
